Abstract
Patients and animals with GM-CSF-producing tumors have an increased number of mobilized CD34+ progenitor cells within their peripheral blood and tumor tissue. These CD34+ cells are inhibitory to the activity of intratumoral T-cells. The present study used the murine Lewis lung carcinoma (LLC) model to assess mechanisms that could lead to the accumulation of CD34+ cells within the tumor tissue. In vitro analyses showed that LLC tumor explants released chemoattractants for normal femoral CD34+ cells. The LLC tumor cells contributed to the production of this activity since CD34+ cell chemoattractants were also released by cultured LLC cells. Antibody neutralization studies showed that most, although not all, of the chemotactic activity that was produced by LLC cells could be attributed to VEGF. In vivo studies with fluorescent-tagged CD34+ cells showed their accumulation within the tumor tissue, but not within the lungs, spleen or bone marrow, suggesting a selective accumulation within the tumor. Whether or not VEGF could chemoattract CD34+ cells in vivo was measured with a VEGF-containing Matrigel plug assay. Infusion of fluorescent-tagged CD34+ cells into mice after the plugs became vascularized revealed the accumulation of fluorescent-tagged cells within the plugs. However, these CD34+ cells failed to accumulate within the VEGF-containing Matrigel plugs when they were infused together with neutralizing anti-VEGF antibody. Through a combination of in vitro and in vivo analyses, the LLC cells were shown to be capable of chemoattracting CD34+ cells, with most of the tumor-derived chemotactic activity being due to tumor release of VEGF.
Article PDF
Similar content being viewed by others
References
Wright MA, Wiers K, Vellody K et al. Stimulation of immune suppressive CD34+ cells from normal bone marrow by Lewis lung carcinoma tumors. Cancer Immunol Immunother 1998; 46: 253–60.
Young MRI, Wright MA, Matthews JP et al. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-? and nitric oxide. J Immunol 1996; 156: 1916–22.
Young MRI, Wright MA, Coogan M et al. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor ?. Cancer Immunol Immunother 1992; 35: 14–8.
Young MRI, Schmidt-Pak A, Wright MA et al. Mechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34+ cells in cancers that secrete granulocytemacrophage colony-stimulating factor. Clin Cancer Res 1995; 1: 95–103.
Pandit R, Wright MA, Garrity T et al. CD34+ immune suppressor cells in the blood of head and neck cancer patients. Ann Otol Rhinol Laryngol 2000; in press.
Garrity T, Pandit R, Wright MA et al. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into CD1a+ cells. Int J Cancer 1997; 73: 663–9.
Young MRI, Wright MA, Lozano Y et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67: 333–8.
Young KM, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987; 47: 100–5.
Wiers KM, Wright MA, Lathers DMR et al. Vitamin D3 treatmentto diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. J Immunother 2000; 23: 115-24.
Young MRI, Wright MA. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: interferon ? plus tumor necrosis factor-? synergistically reduce immune suppressor and tumor growth-promoting activities of bone marrow cells, and diminish tumor recurrence and metastasis. Cancer Res 1992; 52: 6335–40.
Hirashima M, Kataoka H, Nishikawa S et al.Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 1999; 93: 1253–63.
Schofield KP, Rushton g, Humphries MJ et al. Influence of interleukin-3 and other growth factors on ?4?1 integrin-mediated adhesion and migration of human hematopoietic progenitor cells. Blood 1997; 90: 1858–66.
Dutt P, Wang JF, Groopman JE. Stromal cell-derived factor-1? and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: A potential mechanism for cooperative induction of chemotaxis. J Immunol 1998; 161: 3652–58.
Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: Stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998; 91: 100–10.
Aiuti A, Webb IJ, Bleul C et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111–20.
Young MR, Wright MA, Lathers DM et al. Increased resistance to apoptosis by bone marrow CD34+ progenitor cells from tumorbearing mice. Int J Cancer 1999; 82: 609–15.
Young MRI, Wright MA, Vellody K et al. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the reduction of differentiation toward dendritic cells by 1?,25-dihydroxyvitamin D3. Int J Immunopharmacol 1999; 21: 675–88.
Metz R, Vellody K, Patel S et al. Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A. Inv Met 1997; 16: 280–90.
Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–7.
Prewett M, Huber J, Li Y et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–18.
Sauter ER, Nesbit M, Watson JC et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999; 5: 775–82.
Claffey KP, Brown LF, del Anguila LF et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172–81.
Bronte V, Chappell DB, Apolloni E et al. Unopposed productionof granulocyte-macrophage colony-stimulating factor by tumor inhibitors CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 5728–37.
Steube KG, Meyer C, Drexler HG. Secretion of functional hematopoietic growth factors by human carcinoma cell lines. Int J Cancer 1998; 78: 120–4.
Lang SH, Miller WR, Duncan W et al. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. Int J Cancer 1994; 59: 235–41.
Lathers DMR, Lubbers E, Wright MA et al. Dendritic cell differentiation pathways of CD34+ cells from the peripheral blood of head and neck cancer patients. J Leukoc Biol 1999; 65: 623–8.
Wiers K, Wright MA, Vellody K et al. Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels. Clin Exp Met 1998; 16: 275–82.
Takahashi T, Kalka C, Masuda H et al. Ischemia-and cytokineinduced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434–8.
Folkman J. The role of angiogenesis in tumor growth. Sem Cancer Biol 1992; 3: 65–71.
Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629–34.
Isaji M, Miyata H, Ajisawa Y et al. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol 1997; 122: 1061–6.
Nissen NN, Polverini PJ, Koch AE et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445–52.
Joraschkewitz M, Depenbrock H, Freund M et al. Effects of cytokines on in vitro colony formation of primary human tumour specimens. Eur J Cancer 1992; 26: 1070–4.
Burke F, Relf M, Negus R et al. A cytokine profile of normal and malignant ovary. Cytokine 1996; 8: 578–85.
Mrowietz U, Schwenk U, Maune S et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999; 79: 1025–31.
Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373–86.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Young, M.R.I., Kolesiak, K., Wright, M.A. et al. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis 17, 881–888 (1999). https://doi.org/10.1023/A:1006708607666
Issue Date:
DOI: https://doi.org/10.1023/A:1006708607666